Dividends

Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 14, 2020

Gilead Sciences, Inc. (GILD) will begin trading ex-dividend on September 14, 2020. A cash dividend payment of $0.68 per share is scheduled to be paid on September 29, 2020. Shareholders who purchased GILD prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that GILD has paid the same dividend. At the current stock price of $63.77, the dividend yield is 4.27%.

The previous trading day's last sale of GILD was $63.77, representing a -25.82% decrease from the 52 week high of $85.97 and a 4.73% increase over the 52 week low of $60.89.

GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. (AMGN) and Biogen Inc. (BIIB). GILD's current earnings per share, an indicator of a company's profitability, is -$.24. Zacks Investment Research reports GILD's forecasted earnings growth in 2020 as 13.23%, compared to an industry average of 12.7%.

For more information on the declaration, record and payment dates, visit the GILD Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.

Interested in gaining exposure to GILD through an Exchange Traded Fund [ETF]?
The following ETF(s) have GILD as a top-10 holding:

  • VanEck Vectors Biotech ETF (BBH)
  • iShares Nasdaq Biotechnology Index Fund (IBB)
  • Invesco Dynamic Biotech & Genome ETF (PBE)
  • Invesco Dynamic Pharmaceuticals ETF (PJP)
  • Columbia Sustainable U.S. Equity Income ETF (ESGS).

The top-performing ETF of this group is ESGS with an increase of 15.54% over the last 100 days. BBH has the highest percent weighting of GILD at 8.68%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

NASDAQ.com

Nasdaq

Get the latest stock market news, stock information & quotes, data analysis reports, as well as a general overview of the market landscape from Nasdaq.

Read Nasdaq.com's Bio